ReviewDiscover oncology2025
Non-coding RNAs in programmed cell death regulation in melanoma: mechanisms and therapeutic insights.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma, the most deadly type of skin cancer that develops from melanocytes, has seen its sharp increase in occurrence worldwide, especially with increased UV radiation exposure., making it a serious public health problem. Despite significant improvements in early diagnosis and treatment techniques, effectively treating melanoma patients, particularly those with metastatic cancer. Resistance to programmed cell death is a characteristic of many malignancies, including melanoma, which affects cellular development, survival, metastasis, and treatment resistance. Non-coding RNAs have been shown in recent research to be essential regulators of several biological processes, including programmed cell death. Research indicates that ncRNAs can have either pro-tumorigenic (causing resistance to cell death) or anti-tumorigenic (causing cell death) effects, making them attractive targets for therapy as well as prognostic and diagnostic biomarkers. This paper thoroughly examines the role of ncRNAs in controling among other types of designed cell death in melanoma, such as anoikis, pyroptosis, ferroptosis, autophagy, necroptosis, apoptosis, cuproptosis, and netosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.